Komori
Other Disclosures4554Fuji Pharma Co.,Ltd.Pharmaceuticals

Notice of the Start of Promotion of “Papilocare Vaginal gel” by TaiOLIC

OLIC has begun promotional activities in Thailand for Papilocare® Vaginal gel, an HPV-related vaginal gel. The company is targeting a sales launch in July 2026.

Worth reading
70In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Papilocare® Vaginal gel
Applicable field (uses covered by this announcement)

HPV-related cervical lesions and HPV clearance, and women's healthcare

Launch dateJuly 2026 (sales launch planned)
Contract DateJanuary 2025
What the company reported numerically
Usage history

Sold in more than 65 countries and used by more than 1 million women (currently)

Relationship between the counterparty and the company
Fuji Pharma Co.,Ltd.4554
Relationship with the Company

OLIC (Thailand) Limited, a group company of the Company, entered into an exclusive distribution rights agreement for Thailand with Procare Health Iberia, S.L. in January 2025.

CounterpartyProcare Health Iberia, S.L.

Headquartered in Valencia, Spain, Procare Health is a Spanish pharmaceutical company focused on the research, development, manufacturing and sale of natural-origin, scientifically proven solutions for women's health and well-being. Founded in 2012, the company is 100% privately held.

Awarding / certifying body

Thai FDA (medical device approval)

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Procare Health and reports on clinical research and usage worldwide

Announced details
ItemDetails
Names of Products / Services CoveredPapilocare® Vaginal gel
CounterpartyProcare Health Iberia, S.L.
Counterparty overviewHeadquartered in Valencia, Spain, Procare Health is a Spanish pharmaceutical company focused on the research, development, manufacturing and sale of natural-origin, scientifically proven solutions for women's health and well-being. Founded in 2012, the company is 100% privately held.
Relationship with the CompanyOLIC (Thailand) Limited, a group company of the Company, entered into an exclusive distribution rights agreement for Thailand with Procare Health Iberia, S.L. in January 2025.
Contract DateJanuary 2025
Launch dateJuly 2026 (sales launch planned)
Applicable areaHPV-related cervical lesions and HPV clearance, and women's healthcare
Awarding / certifying bodyThai FDA (medical device approval)
Usage historySold in more than 65 countries and used by more than 1 million women (currently)
SourceProcare Health and reports on clinical research and usage worldwide
Items this document does not state (8)
Contract ValueOffering priceAward/certification nameRegistration number and expiry dateLocationLocation scaleQuantitative EffectsImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To expand its contribution to women's healthcare and create new value.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Start of Promotion of “Papilocare Vaginal gel” by TaiOLIC | Fuji Pharma Co.,Ltd. (4554) timely disclosure | Komori